Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection - PubMed (original) (raw)
. 2021 Aug 16;224(4):595-605.
doi: 10.1093/infdis/jiab283.
Dung Nguyen 1, Matthew Fish 2, Jennifer Rynne 2, Aislinn Jennings 2, Sarah Williams 1, Farah Al-Beidh 3, David Bonsall 4 5, Amy Evans 6, Tanya Golubchik 5, Anthony C Gordon 3 7, Abigail Lamikanra 8, Pat Tsang 8, Nick A Ciccone 9, Ullrich Leuscher 8, Wendy Slack 8, Emma Laing 6, Paul R Mouncey 10, Sheba Ziyenge 11, Marta Oliveira 11 12, Rutger Ploeg 11 12, Kathryn M Rowan 10, Manu Shankar-Hari 2 13, David J Roberts 8 9, David K Menon 14, Lise Estcourt 6 9, Peter Simmonds 1, Heli Harvala 15; REMAP-CAP Immunoglobulin Domain UK Investigators
Affiliations
- PMID: 34031695
- PMCID: PMC8241475
- DOI: 10.1093/infdis/jiab283
Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection
Jeremy Ratcliff et al. J Infect Dis. 2021.
Abstract
Background: Convalescent plasma containing neutralizing antibody to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is under investigation for coronavirus disease 2019 (COVID-19) treatment. We report diverse virological characteristics of UK intensive care patients enrolled in the Immunoglobulin Domain of the REMAP-CAP randomized controlled trial that potentially influence treatment outcomes.
Methods: SARS-CoV-2 RNA in nasopharyngeal swabs collected pretreatment was quantified by PCR. Antibody status was determined by spike-protein ELISA. B.1.1.7 was differentiated from other SARS-CoV-2 strains using allele-specific probes or restriction site polymorphism (SfcI) targeting D1118H.
Results: Of 1274 subjects, 90% were PCR positive with viral loads 118-1.7 × 1011IU/mL. Median viral loads were 40-fold higher in those IgG seronegative (n = 354; 28%) compared to seropositives (n = 939; 72%). Frequencies of B.1.1.7 increased from <1% in November 2020 to 82% of subjects in January 2021. Seronegative individuals with wild-type SARS-CoV-2 had significantly higher viral loads than seropositives (medians 5.8 × 106 and 2.0 × 105 IU/mL, respectively; P = 2 × 10-15).
Conclusions: High viral loads in seropositive B.1.1.7-infected subjects and resistance to seroconversion indicate less effective clearance by innate and adaptive immune responses. SARS-CoV-2 strain, viral loads, and antibody status define subgroups for analysis of treatment efficacy.
Keywords: COVID-19; ELISA; SARS-CoV-2; clade B.1.1.7; convalescent plasma; coronavirus; polymerase chain reaction; randomized clinical trial; variant of concern; viral load.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Figures
Figure 1.
Comparison of viral loads in anti-SARS-CoV-2 seropositive and seronegative subjects. A, C, and D, Associations of anti-SARS-CoV-2 antibody status, invasive ventilation, and immunosuppression on viral load distributions as determined by RT-qPCR of pretreatment respiratory samples. Median values shown to the right of Tukey box plots. Distributions were compared by Mann-Whitney U test. B, Frequency of seropositivity in individuals with different viral loads quantified in respiratory samples. Abbreviations: IgG, immunoglobulin G; RT-qPCR, reverse transcription quantitative polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Figure 2.
Temporal emergence of the SARS-CoV-2 B.1.1.7 clade. Proportion of subjects with the B.1.1.7 clade virus enrolled to the REMAP-CAP trial in different weeks over the study period compared to proportions in the wider UK population from sequences deposited in GISAID. Numbers at the top of the graph indicate total enrolments/week. Abbreviations: GISAID, Global Influenza Surveillance and Response System REMAP-CAP, Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Figure 3.
Viral loads of wild-type and B.1.1.7 strains in seronegative and seropositive subjects. Distributions of viral loads of in samples from patients infected with wild-type and B.1.1.7 strains, subdivided by serostatus. Distributions were compared by Mann-Whitney U test test. Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WT, wild type.
Similar articles
- Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
Thomopoulos TP, Rosati M, Terpos E, Stellas D, Hu X, Karaliota S, Bouchla A, Katagas I, Antoniadou A, Mentis A, Papageorgiou SG, Politou M, Bear J, Donohue D, Kotanidou A, Kalomenidis I, Korompoki E, Burns R, Pagoni M, Grouzi E, Labropoulou S, Stamoulis K, Bamias A, Tsiodras S, Dimopoulos MA, Pavlakis GN, Pappa V, Felber BK. Thomopoulos TP, et al. Viruses. 2021 Sep 15;13(9):1844. doi: 10.3390/v13091844. Viruses. 2021. PMID: 34578426 Free PMC article. Clinical Trial. - Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L, Zody MC, Di Germanio C, Martinelli R, Mediavilla JR, Cunningham MH, Composto K, Chow KF, Kordalewska M, Corvelo A, Oschwald DM, Fennessey S, Zetkulic M, Dar S, Kramer Y, Mathema B, Germer S, Stone M, Simmons G, Busch MP, Maniatis T, Perlin DS, Kreiswirth BN. Chen L, et al. mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21. Epub 2021 Aug 25. mSphere. 2021. PMID: 34431691 Free PMC article. - Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
Kaku Y, Kuwata T, Zahid HM, Hashiguchi T, Noda T, Kuramoto N, Biswas S, Matsumoto K, Shimizu M, Kawanami Y, Shimura K, Onishi C, Muramoto Y, Suzuki T, Sasaki J, Nagasaki Y, Minami R, Motozono C, Toyoda M, Takahashi H, Kishi H, Fujii K, Tatsuke T, Ikeda T, Maeda Y, Ueno T, Koyanagi Y, Iwagoe H, Matsushita S. Kaku Y, et al. Cell Rep. 2021 Jul 13;36(2):109385. doi: 10.1016/j.celrep.2021.109385. Epub 2021 Jun 25. Cell Rep. 2021. PMID: 34237284 Free PMC article. - Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
Lu L, Zhang H, Zhan M, Jiang J, Yin H, Dauphars DJ, Li SY, Li Y, He YW. Lu L, et al. Sci China Life Sci. 2020 Dec;63(12):1833-1849. doi: 10.1007/s11427-020-1859-y. Epub 2020 Dec 1. Sci China Life Sci. 2020. PMID: 33355886 Free PMC article. Review. - Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.
Focosi D, Maggi F. Focosi D, et al. Rev Med Virol. 2021 Nov;31(6):e2231. doi: 10.1002/rmv.2231. Epub 2021 Mar 16. Rev Med Virol. 2021. PMID: 33724631 Free PMC article. Review.
Cited by
- Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial.
Fish M, Rynne J, Jennings A, Lam C, Lamikanra AA, Ratcliff J, Cellone-Trevelin S, Timms E, Jiriha J, Tosi I, Pramanik R, Simmonds P, Seth S, Williams J, Gordon AC, Knight J, Smith DJ, Whalley J, Harrison D, Rowan K, Harvala H, Klenerman P, Estcourt L, Menon DK, Roberts D, Shankar-Hari M; REMAP-CAP Immunoglobulin Domain UK Investigators. Fish M, et al. Intensive Care Med. 2022 Nov;48(11):1525-1538. doi: 10.1007/s00134-022-06869-w. Epub 2022 Sep 14. Intensive Care Med. 2022. PMID: 36102943 Free PMC article. Clinical Trial. - Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR.
Ratcliff J, Al-Beidh F, Bibi S, Bonsall D, Costa Clemens SA, Estcourt L, Evans A, Fish M, Folegatti PM, Gordon AC, Jay C, Jennings A, Laing E, Lambe T, MacIntyre-Cockett G, Menon D, Mouncey PR, Nguyen D, Pollard AJ, Ramasamy MN, Roberts DJ, Rowan KM, Rynne J, Shankar-Hari M, Williams S, Harvala H, Golubchik T, Simmonds P; AMPHEUS Project, REMAP-CAP Immunoglobulin Domain UK Investigators, and Oxford COVID-19 Vaccine Trial Group. Ratcliff J, et al. J Clin Microbiol. 2022 Apr 20;60(4):e0228321. doi: 10.1128/jcm.02283-21. Epub 2022 Mar 24. J Clin Microbiol. 2022. PMID: 35321556 Free PMC article. - Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.
Lingas G, Néant N, Gaymard A, Belhadi D, Peytavin G, Hites M, Staub T, Greil R, Paiva JA, Poissy J, Peiffer-Smadja N, Costagliola D, Yazdanpanah Y, Wallet F, Gagneux-Brunon A, Mentré F, Ader F, Burdet C, Guedj J, Bouscambert-Duchamp M. Lingas G, et al. J Antimicrob Chemother. 2022 Apr 27;77(5):1404-1412. doi: 10.1093/jac/dkac048. J Antimicrob Chemother. 2022. PMID: 35233617 Free PMC article. Clinical Trial. - Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection.
Hwang YC, Lu RM, Su SC, Chiang PY, Ko SH, Ke FY, Liang KH, Hsieh TY, Wu HC. Hwang YC, et al. J Biomed Sci. 2022 Jan 4;29(1):1. doi: 10.1186/s12929-021-00784-w. J Biomed Sci. 2022. PMID: 34983527 Free PMC article. Review. - Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma.
Nguyen D, Xiao J, Simmonds P, Lamikanra A, Odon V, Ratcliff J, Townsend A, Roberts DJ, Harvala H. Nguyen D, et al. J Infect Dis. 2022 Mar 15;225(6):971-976. doi: 10.1093/infdis/jiab563. J Infect Dis. 2022. PMID: 34751775 Free PMC article.
References
- World Health Organization. WHO coronavirus (COVID-19) dashboard.https://covid19.who.int. Accessed 12 May 2021.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous